Here is what you need to know on Tuesday, October 19:
Equity markets turned on early bears yesterday and surged higher with riskier assets showing the biggest gains. The meme stock space was back. Crypto stocks surged on Bitcoin, and tech favourites were also strong as investors focused on strong earnings growth over yields and energy prices. Yields did at least retreat somewhat during the day, allowing the Nasdaq space to breathe, but energy prices continue to rise and portend bumps ahead for growth stocks. Netflix (NFLX) (see more) and Tesla (TSLA) shares continued their recent strong performances from both, with Netflix reporting after the close while Tesla is up tomorrow. We have been resolutely bullish on Tesla (see more) for some time but feel that both stocks may have run too far ahead of earnings.
The dollar has finally calmed down and stopped its recent surge and is now back at 1.1654 versus the euro. Oil remains strong at $83.30, and Bitcoin is has everyone's focus at $62,100. Gold is at $1,781, Vix dropped to 16 and the US 10-year yield is now 1.58%.
See forex today
European markets are higher: Eurostoxx +0.3%, FTSE +0.2% and Dax +0.1%.
US futures are higher: S&P +0.5%, Dow +0.5% and Nasdaq +0.4%.
Wall Street (SPY) (QQQ) stock news
Walmart (WMT): Goldman Sachs adds to its conviction buy list.
Proctor & Gamble (PG) beat earnings estimates, but shares fall as it says it will raise prices to counter supply costs.
GOOGL, AMZN: Reuters reports about 12 Senators are proposing a bill barring big tech companies from favouring their own products and services.
Johnson & Johnson (JNJ) is also down despite beating earnings estimates.
Bank of New York (BK) earnings beat on top and bottom lines.
Harmony Bio (HRMY) to enter S&P Small Cap 600.
GameStop (GME): SEC report says short selling was not the main cause of the huge spike in GME.
Haliburton (HAL) misses on revenue, in line on EPS, shares fall 1% premarket.
Phillip Morris (PM): EPS comes in ahead of estimates.
Ford (F) rolls first Mustang Mach E electric vehicle off Chinese assembly line.
Adagio Thera (ADGI) up 7% on positive data from covid trial.
Atea Pharma (AVIR) down sharply on trial not meeting its endpoint.
Alibaba (BABA) says it has made a custom chip that is to be used in its data centre servers, up 2% premarket.
DLocal (DLO) down 7% on secondary offering.
Manpower Group (MAN) down on Q4 earnings.
Pfizer (PFE), BioNTech (BNTX): FDA may allow vaccine mix and match this week, according to NYTimes.
Silvergate (SI) beats on EPS and revenue, stock down 4% premarket.
Earnings, Upgrades, downgrades and premarket
Source: Benzinga Pro
Economic releases
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD extends gains above 1.0700, focus on key US data
EUR/USD meets fresh demand and rises toward 1.0750 in the European session on Thursday. Renewed US Dollar weakness offsets the risk-off market environment, supporting the pair ahead of the key US GDP and PCE inflation data.
GBP/USD extends recovery above 1.2500, awaits US GDP data
GBP/USD is catching a fresh bid wave, rising above 1.2500 in European trading on Thursday. The US Dollar resumes its corrective downside, as traders resort to repositioning ahead of the high-impact US advance GDP data for the first quarter.
Gold price edges higher amid weaker USD and softer risk tone, focus remains on US GDP
Gold price (XAU/USD) attracts some dip-buying in the vicinity of the $2,300 mark on Thursday and for now, seems to have snapped a three-day losing streak, though the upside potential seems limited.
Injective price weakness persists despite over 5.9 million INJ tokens burned
Injective price is trading with a bearish bias, stuck in the lower section of the market range. The bearish outlook abounds despite the network's deflationary efforts to pump the price.
US Q1 GDP Preview: Economic growth set to remain firm in, albeit easing from Q4
The United States Gross Domestic Product (GDP) is seen expanding at an annualized rate of 2.5% in Q1. The current resilience of the US economy bolsters the case for a soft landing.